Clinical effects of different doses of ligustrazine on spinal cord injury

Du Fangtao; Fang Jifeng; Li Xingjing; Qiao Peiliu; Li Guangyi

doi:10.3760/j.issn.1673-4777.2019.10.017

Abstract：Objective To observe the clinical effects of different doses of ligustrazine on spinal cord injury. Methods Ninety non-surgical patients with spinal cord injury admitted to the Second People′s Hospital of Liaocheng Taishan Medical College from January 2017 to May 2018 were randomly divided into control group and observation group, with 45 cases in each group. The control group was given intravenous drip of ligustrazine 120 mg while the observation group was given intravenous drip of ligustrazine 240 mg on the basis of routine treatment. Expressions of tumor necrosis factor-α( TNF-α) and interleukin-1β( IL-1β) mRNA in cerebrospinal fluid, Botsford score and Functional Independence Measure( FIM) score were analyzed before and after treatment. Results There were no significant differences of TNF-αand IL-1βmRNA contents in cerebrospinal fluid between groups before treatment ( both P > 0. 05 ) . After treatment, levels of TNF-α and IL-1β mRNA significantly decreased in both groups, and the levels in observation group were lower than those in control group [ ( 0. 12 ± 0. 04)ng/L vs (0. 29 ± 0. 08)ng/L, (0. 110 ± 0. 012)ng/L vs (0. 280 ± 0. 070)ng/L](all P<0. 01). There were no significant differences of Botsford score and FIM score between groups before treatment(P>0. 05). After treatment, Botsford score and FIM score were significantly improved and the scores in observation group were higher than those in control group[(24.2 ±4.8) vs (20.9 ±2.8), (111 ±11) vs (90 ±11)](all P<0.05). Conclusions Ligustrazine may promote the rehabilitation of spinal cord injury by affecting expressions of TNF-αand IL-1β in cerebrospinal fluid. The therapeutic effect of high dose ligustrazine is more remarkable.